SEARCH OF NEW PROGNOSTIC MARKERS OF EFFICACY OF THERAPY WITH TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA PATIENTS USING EXOME SEQUENCING

Background. Chronic myeloid leukemia (CML) is a common myeloproliferative disease characterized by pathologic activity of the fusion gene BCR/ABL, which encodes a tyrosine kinase that stimulates uncontrolled cell proliferation and DNA instability. Up to 20% of CML patients demonstrate primary resistance or non-optimal response to targeted tyrosine-kinase inhibitors (TKI) therapy.
Objective. To find new potential genetic markers of TKI resistance by whole exome sequencing.
Materials and methods. The study included eight patients with Ph+ CML in the chronic phase (CF). After 6 months of follow-up period patients were divided into two groups: four with an optimal response to TKI therapy and four with a non optimal response. The validation group included 62 patients (32 with optimal and 30 with non-optimal response to therapy). Exome sequencing was performed using the Ion Torrent PGM platform. Alignment was performed on the human genome (GRCh37). Sanger sequencing was conducted on an ABI PRISM 3500xl . Statistical processing of the results was carried out using MS Office Excel and SPSS21.
Results and conclusion. Exome sequencing revealed seven single-nucleotide variants (SNVs) associated with therapy outcomes: ANKRD35-rs11579366, DNAH9- rs1990236, MAGEC1-rs176037, TOX3-rs10653661, THSD1-rs3803264, MORN2-rs3099950, and PTCRArs9471966. Validation of these variants in 62 patients did not confirm prognostic role of any of the individual SNVs or their combinations. An additional analysis of the number of SNVs in 9000 genes revealed 75 genes with significant differences in the number of SNVs. Enrichment analysis showed that these genes are involved in cell adhesion, cell contacts, T-cell antigen activation, and inhibition of IFNα-mediated antiproliferative signaling. Many of these genes are also associated with a variety of cancers (renal, lung and breast cancer). Possible multifactorial nature of the efficacy of therapy complicates the search of new prognostic markers.

1. Kulikov S. M., Vinogradova O. Iu., Chelysheva E. Iu. et al. Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009—2012 population-based study. Terapevticheskij arkhiv 2014; 86(7):24—30 (in Russian).

2. Hoffmann V. S., Baccarani M., Hasford J. et al. The EUTOS populationbased registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia 2015; 29(6):1336—1343.

3. Jabbour E., Kantarjian H., Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clinical Lymphoma Myeloma and Leukemia 2015; 15(6):323—334.

4. Volkova S. A., Samojlova O. S., Samarina I. N. et al. Efficiency of imatinib and the prognostic importance of treatment failure according to ELN criteria after 18 months in out-patient therapy of chronic myeloid leukemia. Klinicheskaja onkogematologija. Fundamental’nye issledovanija i klinicheskaja praktika 2011; 4(2):146—151 (in Russian).

5. Bixby D., Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011; 25(1):7—22.

6. Kutsev S. I., Evolution of therapy monitoring of chronic myeloid leukemia. Gematologija i transfuziologija 2009; 54(4):36—44 (in Russian).

7. Hamad A., Sahli Z., E Sabban M. et al. Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. Stem Cells International 2013; 2013:724360. doi: 10.1155/2013/724360.

8. Marin D., Ibrahim A. R., Goldman J. M. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. Clin Oncol 2011; 29(29):3944—3945.

9. Yamamoto E., Fujisawa S., Hagihara M. et al. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci 2014; 105(1):105—109.

10. Gromicho M., Magalhães M., Torres F. et al. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncology Reports 2013; 29(2):741—750.

11. de Lima L. T., Vivona D., Bueno C. T. et al. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Med Oncol. 2014; 31(3):851.

12. Šmahelová J., Kaštánková I., Poláková K. M. et al. Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia. Oncology Reports 2017; 37(1):547—554.

13. Ben Hassine I., Gharbi H., Soltani I. et al. hOCT1 gene expression predict for optimal response to imatinib in Tunisian patients with chronic myeloid leukemia. Cancer Chemotherapy Pharmacology 2017; 79(4):737—745.

14. Harrach S., Schmidt-Lauber C., Pap T. et al. MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients. Blood Cancer J. 2016; 6(9):e470.

15. Frank O., Brors B., Fabarius A. et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006; 20(8):1400—1407.

16. San Jose-Eneriz E., Roman-Gomez J., Jimenez-Velasco A. et al. Micro RNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009; 8:69.

17. Angelini S., Soverini S., Ravegnini G. et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 2013; 98(2):193—200.

18. Bourgne C., Janel A., Berger J. et al. Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk348) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML). Leukemia Research 2015; 39(3):329—334.

19. Barreyro L., Will B., Bartholdy B. et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012; 120(6):1290—1298.

20. Pellicano F., Sinclair A., Holyoake T. L. In search of CML stem cells’ deadly weakness. Current Hematologic Malignancy Reports 2011; 6(2):82—87.

21. Zhao K., Yin L. L., Zhao D. M. et al. IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients. Int J Clin Exp Med 2014; 7(12):4787—4798.

22. Zheng Q., Cao J., Hamad N. et al. Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. Journal of Translational Medicine 2016; 14:82; doi: 10.1186/s12967-016-0837-5.

23. Kotagama K., Chang Y., Mangone M. miRNAs as biomarkers in chronic myelogenous leukemia. Drug Development Research 2015; 76(6):278—285.

24. Nievergall E., Reynolds J., Kok C. H. et al. TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia 2016; 30(6):1263—1272.

25. Baccarani M., Deininger M. W., Rost G. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122(6):872—884.

26. Lavrov A. V., Chelysheva E. Y., Smirnikhina S. A. et al. Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia. BMC Genetics 2016; 17(1):14. doi: 10.1186/s12863-015-0308-7.

27. Smirnikhina S. A., Lavrov A. V., Chelysheva E. Y. et al. Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients. Leukemia Lymphoma 2016; 57(7):1669—1676.

28. Lake S. L., Lyon H., Tantisira K. et al. Estimation and tests of haplotypeenvironment interaction when linkage phase is ambiguous. Hum Hered 2003; 55(1):56—65.

29. Chen E. Y., Tan C. M., Kou Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 2013; 14:128; doi: 10.1186/1471-2105-14-12.

30. Kuleshov M. V., Jones M. R., Rouillard A. D. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Research 2016; 44(W1):W90-7; doi: 10.1093/nar/gkw377.

31. Pletscher-Frankild S., Pallejà A., Tsafou K. et al. DISEASES: Text mining and data integration of disease–gene associations. Methods 2015; 74:83—89; doi: 10.1016/j.ymeth.2014.11.020.

32. Huang Y., Zheng J., Hu J. D. et al. Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing. Genetics and Molecular Research2014; 13(1):945—953.

33. Sabri S., Keyhani M., Akbari M.T. Whole exome sequencing of chronic myeloid leukemia patients. Iran J Public Health. 2016; 45(3):346—352.

34. Raaijmakers J. H., Bos J. L. Specificity in Ras and Rap signaling. J Biol Chem. 2009; 284(17):10995—10999.

35. Bhattacharya S., Zheng H., Tzimas C. et al. Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. Blood 2011; 118(15):4179—4187.